Kura Oncology to Report Second Quarter 2025 Financial Results
Kura Oncology (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, has scheduled its second quarter 2025 financial results announcement for Thursday, August 7, 2025, after U.S. market close.
The company will host a conference call and webcast at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and provide a corporate update. Investors can access the call via phone or webcast through the company's investor relations website.
Kura Oncology (Nasdaq: KURA), un'azienda biofarmaceutica in fase clinica specializzata in terapie di precisione per il trattamento del cancro, ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per giovedì 7 agosto 2025, dopo la chiusura dei mercati statunitensi.
L'azienda terrà una conference call e una webcast alle 16:30 ET / 13:30 PT per discutere i risultati e fornire un aggiornamento aziendale. Gli investitori potranno partecipare alla chiamata telefonicamente o tramite webcast accedendo al sito web delle relazioni con gli investitori della società.
Kura Oncology (Nasdaq: KURA), una empresa biofarmacéutica en etapa clínica enfocada en medicamentos de precisión para el tratamiento del cáncer, ha programado el anuncio de resultados financieros del segundo trimestre de 2025 para el jueves 7 de agosto de 2025, después del cierre del mercado en EE.UU.
La compañía realizará una llamada conferencia y una transmisión en vivo a las 4:30 p.m. ET / 1:30 p.m. PT para discutir los resultados y ofrecer una actualización corporativa. Los inversores podrán acceder a la llamada por teléfono o a través de la transmisión en vivo en el sitio web de relaciones con inversionistas de la empresa.
Kura Oncology (나스닥: KURA)는 암 치료를 위한 정밀 의약품에 중점을 둔 임상 단계의 생명공학 회사로, 2025년 2분기 재무 결과 발표를 2025년 8월 7일 목요일 미국 시장 마감 후에 예정하고 있습니다.
회사는 동부 시간 오후 4시 30분 / 태평양 시간 오후 1시 30분에 컨퍼런스 콜과 웹캐스트를 진행하여 결과를 논의하고 회사 현황을 업데이트할 예정입니다. 투자자들은 회사 투자자 관계 웹사이트를 통해 전화 또는 웹캐스트로 참여할 수 있습니다.
Kura Oncology (Nasdaq : KURA), une société biopharmaceutique en phase clinique spécialisée dans les médicaments de précision pour le traitement du cancer, a prévu l'annonce de ses résultats financiers du deuxième trimestre 2025 le jeudi 7 août 2025, après la clôture des marchés américains.
La société organisera une conférence téléphonique et une diffusion en direct à 16h30 ET / 13h30 PT pour discuter des résultats et fournir une mise à jour de l'entreprise. Les investisseurs pourront accéder à l'appel par téléphone ou via le webcast sur le site des relations investisseurs de la société.
Kura Oncology (Nasdaq: KURA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Präzisionsmedikamente zur Krebsbehandlung spezialisiert hat, hat die Veröffentlichung der Finanzergebnisse für das zweite Quartal 2025 für Donnerstag, den 7. August 2025, nach Börsenschluss in den USA geplant.
Das Unternehmen wird um 16:30 Uhr ET / 13:30 Uhr PT eine Telefonkonferenz und einen Webcast abhalten, um die Ergebnisse zu besprechen und ein Unternehmensupdate zu geben. Investoren können über Telefon oder Webcast über die Investor-Relations-Webseite des Unternehmens teilnehmen.
- None.
- None.
SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report second quarter 2025 financial results after the close of U.S. financial markets on Thursday, August 7, 2025. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing (800) 579-2543 for domestic callers and (785) 424-1789 for international callers and entering the conference ID: KURAQ2. A live webcast and archived replay of the event will be available here or online from the investor relations section of the Company’s website at www.kuraoncology.com.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates designed to target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory (R/R) NPM1-mutant (NPM1-m) acute myeloid leukemia (AML). In November 2024, Kura Oncology entered into a global strategic collaboration agreement with Kyowa Kirin to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in KOMET-001, a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-m AML, has been completed, and in the second quarter of 2025, the companies announced the FDA’s acceptance of a New Drug Application for ziftomenib for the treatment of adult patients with R/R NPM1-m AML and assignment of a Prescription Drug User Fee Act target action date of November 30, 2025. Kura and Kyowa Kirin are conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-m and KMT2A-rearranged AML. Ziftomenib is also being evaluated in a Phase 1 dose-escalation trial (KOMET-015) in combination with imatinib for treatment of patients with advanced gastrointestinal stromal tumors (GIST). KO-2806, a next-generation farnesyl transferase inhibitor (FTI), is being evaluated in a Phase 1 dose-escalation trial (FIT-001) as a monotherapy and in combination with targeted therapies for patients with various solid tumors. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial (KURRENT-HN) in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.
Contacts
Investors and media:
Greg Mann
858-987-4046
gmann@kuraoncology.com
FAQ
When will Kura Oncology (KURA) report Q2 2025 earnings?
How can investors access Kura Oncology's Q2 2025 earnings call?
What time is Kura Oncology's Q2 2025 earnings call?
Where can I find the replay of Kura Oncology's Q2 2025 earnings webcast?
